Dr. Nasry Yassa, CEO and Andrew Brown, Chief Commercial Officer, discuss the use of Fluidigm Mass Cytometry technology within their specialty contract research organization. They have created a specialized CRO business that partners with biopharma to accelerate drug development work, with a focus on introducing novel technologies into early clinical stage development. At this event they focus on the adoption of CyTOF and Imaging Mass Cytometry enabling high parameter single cell proteomics readouts to accelerate therapeutic development for their biopharma clients.
We have implemented advanced microfluidics technology to enable rapid, accurate, lower cost
COVID-19 testing on easy to collect saliva samples.
The Advanta™ SARS-CoV-2 RT-PCR assay was developed by Fluidigm and is supported by an EUA. The assay is a reverse transcription and real-time polymerase chain reaction (RT-PCR) test that leverages Fluidigm microfluidics technology with the Biomark HD platform.
Test results are available within 24h after arrival at our Portland, OR based clinical laboratory.
Sirona Dx is a Portland, Oregon-based technical contract research organization (CRO), which provides high-complexity genomics and proteomics services to pharmaceutical and biotech companies to support drug discovery and development in immuno-oncology. Sirona Dx recently brought the CODEX platform on board to support discovery research with single-cell, spatially resolved multiplex imaging.
To learn how the CRO is accelerating drug discovery and development, and how CODEX will help, we spoke to Andrew Brown, PhD, Chief Commercial Officer at Sirona Dx.
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research
SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sirona Dx, a leader in high-complexity genomics and proteomics services, today announced the introduction of Imaging Mass Cytometry™ services on the Fluidigm Hyperion™ Imaging System to advance biomarker discovery and therapeutic development.
Sirona Dx is a specialized contract research organization (CRO) that provides high-quality clinical research services to pharmaceutical and clinical research clients and focuses on offering early access to advanced technologies.
With a goal of providing innovative approaches to expand drug discovery pipelines and bring more effective therapies to market, Sirona Dx decided to add multiplex tissue imaging to its growing technology portfolio. Noticing impressive Imaging Mass Cytometry results from top pharmaceutical companies and leading academic medical centers, Sirona Dx engaged Akil Merchant, M.D., Assistant Professor at the University of Southern California Keck School of Medicine, as a Scientific Advisor to assess its full potential.
“After a comprehensive evaluation of different tissue imaging technologies, Imaging Mass Cytometry was the clear choice. Imaging Mass Cytometry will enable our clients to resolve complex cellular networks and signaling pathways within tissue microenvironments with unprecedented definition,” said Nasry Yassa, Ph.D., Chief Executive Officer of Sirona Dx. “The early response from our pharma partners has been extremely positive. Our clients are expressing significant interest in using Imaging Mass Cytometry to advance their research goals and are pleased to access this new technology through an experienced CRO. Sirona Dx has exciting projects underway and additional requests coming in from top pharmaceutical companies.”
Developed for research use, Imaging Mass Cytometry enables simultaneous imaging of up to 37 protein markers from a single scan of formalin-fixed, paraffin-embedded (FFPE) or fresh tissue sections at subcellular resolution. Using proven CyTOF® technology, Imaging Mass Cytometry surpasses the inherent limitations of fluorescence detection by using high-purity metal tags that are separated by mass instead of by wavelength. With an established global footprint and 18 scientific publications to date, Imaging Mass Cytometry is rapidly setting a new standard for highly multiplexed tissue imaging.
“By preserving tissue architecture and cellular morphology information, Imaging Mass Cytometry is ideal for understanding complex tissue microenvironments. It is especially useful for monitoring changes in the immune system in a variety of disease states such as cancer or auto-immunity,” said Dr. Merchant. “With easily customizable panel designs using available pre-conjugated antibodies or metal conjugation kits, Imaging Mass Cytometry is a valuable tool for translational and clinical research across a range of disease areas.”
“Sirona Dx is our first Imaging Mass Cytometry CRO partner in the United States,” said Chris Linthwaite, President and CEO of Fluidigm. “Expanding market accessibility is a top priority for unlocking the full potential of Imaging Mass Cytometry. CRO partners play a critical role in providing valuable expertise, accelerating new health insights.”
PORTLAND, Ore., Oct. 30, 2018 /PRNewswire/ -- Sirona Dx, a leader in high complexity genomics and proteomics services, announced today the launch of Oncocyst PD-L1, an assay using IncellDx technology that detects and quantifies abnormal bladder cells and immune cells from urine cytology specimens that express the immune-oncology marker PD-L1 using multi-parameter flow cytometry and bioinformatics. The algorithm also uses aneuploidy/DNA content in cells from the bladder, markers often detected by fluorescence in situ hybridization (FISH) and read using microscopy. The new high throughput assay is non-subjective and can be performed in less than 3 hours.
"The ability to batch large numbers of samples to determine the PD-L1 and DNA content status on abnormal urine cytology specimens represents a major advantage over technologies that require subjective microscopic assessment and dark rooms to read FISH," reports Dr. Nasry Yassa, CEO, Sirona Dx. "We are committed to additional assay development projects with InCellDx to leverage their innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers."
"We are delighted to announce a partnership with Sirona Dx for our novel platform of single cell proteomic and genomic assays using flow cytometry and CTC platforms. With simultaneous 30+ marker capabilities and DNA content on individual cells, we are driving personalized medicine to the cellular level addressing the profound tumor heterogeneity in cancer," added Bruce K. Patterson MD, CEO of IncellDx, Inc.
The two companies look forward to presenting the Oncocyst PD-L1 study data at the IncellDx Corporate Symposia, Wednesday, October 31st, at the Association of Molecular Pathology Meeting in San Antonio TX.
Advanta Immuno-Oncology Gene Expression Assay enables efficient screening of 170 highly informative genes involved in human checkpoint therapeutic response
SOUTH SAN FRANCISCO, Calif., July 18, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the Advanta™ Immuno-Oncology Gene Expression Assay, an optimized qPCR assay that enables efficient interrogation of tumor immunobiology using proven Fluidigm® microfluidic technology. Designed for use with the Biomark™ HD system, the Advanta Immuno-Oncology Gene Expression Assay sensitively detects 170 gene expression markers involved in checkpoint therapeutic response from FFPE and fresh frozen tumor samples. With the capability to analyze biomarkers across defined T cell subsets, immune regulation, immune cell fate, cytokines, chemokines and more, this assay can enable translational researchers to accelerate the development of checkpoint immunotherapies and to identify predictive biomarker signatures for therapeutic response.
Tumor gene expression profiling has proven effective in measuring immune response during cancer progression and therapeutic response. Previous approaches using large preconfigured panels containing hundreds of genes or transcriptome analysis, however, are both costly and time-consuming. Large preconfigured panels can also be difficult to customize for specific experimental needs. The Advanta Immuno-Oncology Gene Expression Assay was developed in collaboration with leading researchers from academia and biopharma to provide the right balance of biomarker breadth, assay flexibility and workflow efficiency.
"Sirona Dx specializes in tumor expression profiling of challenging FFPE samples, and we welcomed the opportunity to partner with Fluidigm to offer the Advanta Immuno-Oncology Gene Expression Assay," said Nasry Yassa, CEO of Sirona Dx. "Our pharma clients are universally impressed with the extremely low input requirements and reduced cost compared to other approaches and are now able to screen more of their precious samples."
The Advanta Immuno-Oncology Gene Expression Assay is available as a two-panel set. The first panel includes 91 key markers of tumor immune response that were previously shown in a multicenter international clinical trial to inform tumor progression and checkpoint therapeutic response. The second panel includes 74 additional highly informative immuno-oncology markers and 17 open assay inlets for additional customization. Both panels contain the same five reference genes and can be purchased and used together or separately.
Combined with Fluidigm microfluidics technology, this Advanta assay uniquely offers significant workflow efficiencies over traditional gene expression profiling methods. Each reaction is miniaturized to nanoliter volume and controlled using precise automation to empower accurate and cost-effective qPCR testing across a large dynamic range. Since assay introduction into the microfluidics circuit is under user control, researchers have the flexibility to add or exchange gene assays within the panel to achieve experimental goals.
"Immunotherapeutic approaches that harness the body's own immune system to fight cancer provide great promise to change how cancer is treated and ultimately cured," said Chris Linthwaite, President and CEO of Fluidigm. "We are excited to announce the Advanta Immuno-Oncology Gene Expression Assay as an expansion of our growing portfolio of workflow solutions for the Biomark HD system to empower this great work. With the launch of this new assay, we are pleased to bring high-value innovation to the cancer research community to help advance the future of cancer care."
VANCOUVER, Wash. - (Nov. 10, 2016) - Sirona Dx, a leader in high complexity genomics and proteomics services, today announced it has adopted Thermo Fisher Scientific's Oncomine Focus Assay to run on the Ion PGM System and expand its drug development and next generation sequencing (NGS) services offered to pharmaceutical and clinical research clients.
Sirona Dx recognizes that pharmaceutical companies require access to genomic expertise as well as multiple platforms and technologies to support oncology clinical research studies. After its comprehensive evaluation and validation, Sirona Dx chose to complement its current service offerings with the Oncomine Focus Assay, which includes 52 solid tumor genes, many associated with current oncology therapies and published evidence.
"We are in a revolutionary time in the world of cancer research. The ability to understand the specific genomic makeup of a tumor and have that information drive drug development and eventually treatment is empowering," said Nasry Yassa, Ph.D., Chief Executive Officer of Sirona Dx. "The Oncomine Focus Assay represents the best of what is available in terms of content and technology."
The assay's content is driven by the Oncomine Knowledgebase, the world's largest curated compendium of cancer genomic information and confirmed with industry-leading pharmaceutical companies, to help enable a more unified approach to companion diagnostic and drug development. It is powered by proven Ion AmpliSeq technology to enable detection of single nucleotide somatic changes, inversions, insertions and deletions, as well as gene fusions and copy number variations using as little as 10ng of formalin-fixed paraffin-embedded (FFPE) DNA and RNA in a single workflow.
"We differentiate ourselves by securing early access to advanced technologies that align with pharma requirements in support of drug development programs," said Charles J. Sailey, MD, MS, FCAP, FASCP, Chief Medical Officer of Sirona Dx. "We are very encouraged by the ability of the Oncomine Focus Assay to enable routine analysis of FFPE samples. To further accelerate drug development programs, we're investigating Ion Torrent solutions for liquid biopsies and circulating tumor cells with plans to offer additional services in the future."
"Pharmaceutical companies are in the midst of a paradigm shift in their drug development strategy, which is leading to a pronounced need for targeted NGS tools that enable precision and efficiency," said Joydeep Goswami, president of clinical next generation sequencing at Thermo Fisher Scientific. "We are proud that Sirona Dx has joined the growing list of partners who have adopted our Oncomine technology in an effort to help the pharma industry develop new therapeutics."
Sirona Dx is a CLIA accredited technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between life science tools developers and translational clinical research, our laboratory offers specialized high complexity single cell proteomics and genomics services to support drug discovery and development programs.